Hong Kong stock market anomaly | BeiPharmaceutical-B(02142.HK) surged more than 4%, announced the release of the first fully human-derived HCAb generation model, speeding up the implementation of the next generation therapy.

According to the Wisdom Financial APP, Haplo Pharmaceutical -B (02142.HK) has risen by more than 4%, as of the time of publication, it has increased by 3.29%, reaching 13.49 Hong Kong dollars, with a trading volume of 52.54 million Hong Kong dollars.